Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

4094 results

Sort By:

POC for the Treatment of Subjects with Moderate AS Using Valvosoft® Non-Invasive Ultrasound Therapy

Study ID: NCT06650839
Start Date: 2025-07-15
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

10

Intervention / Treatment

Kaiwelries

Sponsor

Cardiawave was

Source: clinicaltrials.gov

Share:
Add to list

Real-time Experiences, Physical Activity and Biological Outcomes in Personal Recovery Residents (EMPOWER-RES)

Study ID: NCT06914622
Start Date: 2025-10-06
End Date: 2028-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

Mental Health Recovery Star (MHRS)

Sponsor

IRCCS Centro San Giovanni di Dio Fatebenefratelli

Source: clinicaltrials.gov

Share:
Add to list

From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19

Study ID: NCT06911476
Start Date: 2025-05
End Date: 2025-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment
Sponsor

University Medical Center Groningen

Source: clinicaltrials.gov

Share:
Add to list

Interactive Design of Patient-Specific Molds for Tissue Shaping

Study ID: NCT06711965
Start Date: 2025-05-01
End Date: 2030-08-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

160

Intervention / Treatment

Standard of care reconstruction

Surgery, Breast Mold

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Harmony TPV EMEA PMS

Study ID: NCT06906926
Start Date: 2025-06-01
End Date: 2032-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

80

Intervention / Treatment

Certain imaging assessments can be non-Standard of Care

Sponsor

Medtronic Cardiovascular

Source: clinicaltrials.gov

Share:
Add to list

Restricted or Liberal Fluid for Haemodynamic Resuscitation in Sepsis

Study ID: NCT05453565
Start Date: 2025-11
End Date: 2026-11
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

7838

Intervention / Treatment

Vasopressors

Fluids

Sponsor

Australian and New Zealand Intensive Care Research Centre

Source: clinicaltrials.gov

Share:
Add to list

Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients with Locally Advanced Pancreatic Adenocarcinoma (LAPC)

Study ID: NCT06217666
Start Date: 2025-06-01
End Date: 2028-01-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

24

Intervention / Treatment

PCX-12

Sponsor

ha o name (Carl) Q IU

Source: clinicaltrials.gov

Share:
Add to list

Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer

Study ID: NCT06654466
Start Date: 2025-09-01
End Date: 2027-09
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.

Sponsor

Nest Genomics

Source: clinicaltrials.gov

Share:
Add to list

Routine Application of Point-of-care PCR Test to Identify and Direct Therapy for Acute Respiratory Infection in the Emergency Department Trial

Study ID: NCT06780566
Start Date: 2025-04-30
End Date: 2027-08-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

1050

Intervention / Treatment

Point-of-care PCR testing for respiratory viruses

Laboratory PCR testing for respiratory viruses

Sponsor

The University of Hong Kong

Source: clinicaltrials.gov

Share:
Add to list

Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers

Study ID: NCT06216366
Start Date: 2025-06-15
End Date: 2025-12-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

36

Intervention / Treatment

Sodium Chloride 0.9% Inj pre-exposure

Sodium Chloride 0.9% Inj post-exposure

Recombinant human plasma gelsolin pre-exposure

Recombinant human plasma gelsolin post-exposure

Hyperbaric chamber

Sponsor

BioAegis Therapeutics Inc.

Source: clinicaltrials.gov

Share:
Add to list